ABSTRACT: Nitric oxide (NO) plays a key role in vascular functions and wound healing. A pin-to-hole spark discharge (PHD), which primarily produces NO, recently emerged as an effective tool for medical applications. We therefore investigated whether PHD plasma-produced NO could promote angiogenesis. PHD plasma equipped with a curved tube extension was used to treat a saline solution and porcine aortic endothelial cells in vitro. Both NO and nitrite increased linearly in plasma-treated phosphate buffered saline, and NO also increased in a dose-dependent manner in endothelial cells. PHD plasma treatment induced endothelial cell proliferation and migration. Cells treated for 60 seconds had 8% more cells than untreated samples 5 days after plasma treatment. A 60-second PHD plasma treatment also increased 2D migration distance by 32% compared to an untreated control, whereas the number of cells that migrated through a 3D collagen gel increased by 16%. However, no tube formation was induced by PHD plasma. These data show that PHD plasma could apply NO to accelerate wound healing through enhanced angiogenesis.
I. INTRODUCTION
Nitric oxide (NO) is a bioactive gas that participates in a wide range of physiological reactions. In the vasculature, NO regulates vascular tone, endothelial permeability, smooth muscle cell proliferation, platelet aggregation, and leukocyte adhesion. 1 NO is short lived (half-life 3-30 seconds) and highly soluble in organic solvents, 2 therefore it rapidly diffuses into cells due to its lipophilic nature. NO is generated in cells when NADPH-dependent enzymes called nitric oxide synthases (NOS) convert the amino acid L-arginine into L-citrulline in the presence of oxygen. Constitutively expressed neuronal NOS (nNOS) and endothelial NOS (eNOS) produce NO in nanomolar concentrations (low), while inducible NOS (iNOS) is activated during inflammation to produce micromolar NO concentrations (high). During early wound healing stages, inflammatory cells such as neutrophils and macrophages produce high NO levels to fight infection. 3 As the wound heals, endothelial cells, fibroblasts, and keratinocytes produce lower sustained amounts of NO to stimulate angiogenesis and new tissue formation.
NO promotes endothelial cell survival and angiogenesis, both in vivo and in vitro. The role of NO in angiogenesis was first identified by Pipili-Synetos et al. using a chick Arjunan & Clyne embryo chorioallantoic membrane in vivo model. 4 NO stimulates the enzyme soluble guanylyl cyclase (sGC) which then converts guanosine triphosphate (GTP) into 3,5-cyclic guanosine monophosphate (cGMP), 5 an intracellular second messenger which mediates intracellular NO activity. However, both cGMP-dependent and cGMP-independent pathways have been reported for NO-mediated angiogenesis. [6] [7] [8] cGMP production by NO leads to Akt 9 and ERK 1/2 activation, 10 enhancing cell survival and proliferation, respectively. The cGMP-independent pathway is triggered through S-nitrosylation of the protein Ras, which activates the kinases Raf-1, MEK1 and ERK 1/2 to increase endothelial cell proliferation and migration. 10 NO may also modulate angiogenic factors. Vascular endothelial growth factor (VEGF)-stimulated angiogenesis proceeds through NO production, 11 and both exogenous and endogenous NO enhance fibroblast growth factor-2 (FGF-2) expression. [12] [13] [14] NO also stabilizes hypoxia inducible factor-1α (HIF-1α), which, in turn, up regulates VEGF production. 15 The therapeutic potential of NO in the vasculature was recognized in 1991, 16 and since then NO gas has been used to treat pulmonary hypertension in adults 17, 18 and neonates. 19, 20 However, a major drawback associated with medical grade NO is protecting it from oxidation during storage. NO donor compounds have opened up new ways of treating tissue ischemia by promoting both vasodilation and neovascularization. To promote wound healing in NO-deficient wounds such as diabetic ulcers, various local topical NO delivery systems have been developed. [21] [22] [23] [24] In spite of the enormous potential of NO, only two NO donors are currently in clinical use: sodium nitroprusside and organic nitrates (e.g., glyceryl trinitrate). 25 The limited use of NO donors is attributed to short NO half-life, rapid or inconsistent NO release over a limited time, and NO donor instability. 21, 26, 27 To overcome the limitations of NO gas and donors, several plasma sources were developed to produce high NO concentrations on-site for medical therapy. For example, a rapidly quenched hot-air plasma jet system, the 'Plason', was used in therapeutic mode (t = 40°C) to stimulate wound healing through plasma-produced NO. 28, 29 An NOproducing integrated microwave atmospheric pressure gas-plasma source promoted cell proliferation in primary human keratinocytes and endothelial cells. 30 A pin-to-hole spark discharge (PHD) plasma sterilized liquids and surfaces (including living tissue). [31] [32] [33] [34] [35] [36] We previously demonstrated that PHD plasma delivered NO into liquid and cells without causing significant damage and that PHD plasma treatment enhanced endothelial cell cGMP production. 37 Other plasma sources reported to produce NO include an atmospheric pressure plasma jet (APPJ), a high-frequency plasma source and a pulsed arc discharge.
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plasma devices that deliver NO for wound healing and tissue vascularization.
II. MATERIALS AND METHODS

A. Endothelial cell culture
Porcine aortic endothelial cells (PAEC) were isolated from swine aortae by the collagenase dispersion method. 44 Cells were cultured in low-glucose Dulbecco's modified Eagle's medium (DMEM, Mediatech) supplemented with 5% fetal bovine serum (FBS, Hyclone), 1% penicillin-streptomycin, and 1% L-glutamine (Invitrogen). Cells between passages 4 and 9 were maintained in a humidified incubator at 37°C and 5% CO 2 with medium changes every 2 days.
B. Plasma treatment
A PHD plasma operated in spark mode was ignited in pin-hole electrode configuration, where the central needle-like electrode (1.5 mm diameter) was powered from the positive output of a high-voltage power supply (Figure 1 ). The outer electrode (7 mm diameter) was grounded. The spark discharge had the following characteristics: voltage 4 kV, pulse duration ~ 20 µs, frequency 1-7 Hz, energy per pulse ~1.8 J, plasma diameter 3-5 mm, gas temperature 300-330 K, air flow rate 1 liter/minute. 37, 45 In previous studies, we used gas chromatography to measure rapidly rising NO levels in plasmatreated air, which reached a stable level of 1980 ± 50 ppm NO by 50 seconds of plasma discharge. 37 We also measured reactive oxygen species (ROS), specifically hydrogen peroxide (H 2 O 2 ), and ultraviolet (UV) radiation from the discharge. However, cell exposure to both ROS and UV radiation was decreased to near zero levels by equipping the plasma electrode with either a straight or curved 50-mm Tygon tube extension. 
Nitric oxide measurement in liquid and cells
The fluorescent dye DAF-2 (Cayman Chemicals) was used to measure NO in liquid. DAF-2 detects NO by reacting with N 2 O 3 formed during oxidation of NO to nitrite, yielding a fluorescent compound DAF-2 triazole (DAF-2T). 46 100 µl phosphate buffered saline (PBS) containing 1 µM DAF-2 was added to a 96-well plate (Corning). The solution was treated with PHD plasma for 0-240 pulses, using either the straight or curved tube extension. Fluorescence was measured at ex/em: 485/538 nm using a Tecan Infinite 200 microplate reader. Fluorescence was converted to NO concentration using a standard curve developed using the NO donor, DEA NONOate (Cayman Chemicals). DEA NONOate dissociates with a half-life of 2 min at 37°C to liberate 1.5 moles NO per molecule NONOate. 47 To obtain the standard curve, DEA NONOate (0-1000 nM) dissolved in 0.01 N NaOH was incubated with DAF-2 (1 µM) for 30 min at 37°C and fluorescence measured using a microplate reader as described.
DAF-2 diacetate (DAF-2 DA, Cayman Chemicals), the cell permeant version of DAF-2, was used to measure NO concentration in an endothelial cell monolayer. The non-fluorescent DAF-2 DA is cleaved upon entry into the cell by cellular esterases to DAF-2. 46 PAEC were seeded near confluence in a 96-well plate (30,000 cells/well) and incubated for 24 hours. Prior to plasma treatment, cells were loaded with DAF-2 DA (10 µM) for 45 min. The wells were washed once and 100 µl PBS was added. Cells were treated with PHD plasma for 0-240 pulses using the curved tube extension. To obtain the standard curve, cells pre-loaded with DAF-2DA were incubated with DEA NONOate (0-1000 nM) for 30 min. Fluorescence was measured at ex/em: 485/538 nm in a microplate reader.
Nitrite measurement in liquid
Nitrite concentration in plasma-treated PBS was measured using a Griess reagent kit (Invitrogen). In the Griess assay, the reagent sulfanilic acid reacts with NO 2 -to form a diazonium salt, which is then coupled to a second reagent N-(1-naphthyl)ethylenediamine to form an azo dye. This azo dye can be spectrophotometrically detected. 200 µl PBS was directly treated with PHD plasma (0-240 pulses). A volume of 150 µl treated PBS was incubated with the Griess reagent in a 96-well plate in the dark at room temperature for 30 min. Absorbance was measured at 548 nm using a microplate reader and converted to NO 2 -concentration using a sodium nitrite standard curve.
D. Proliferation assay
Since no significant cell death was previously observed for 0-60 plasma pulses with a curved tube extension, 37 cells were treated at these doses to quantify plasma NO angiogenic effects. Endothelial cell proliferation in response to plasma treatment was measured by cell counts. Approximately 5,000 cells were seeded in 24-well plates and incubated for 24 hours at 37°C. Cells were treated with plasma (0-60 pulses, day 0) and returned to the incubator. Medium was changed on days 2 and 4. On days 1, 3 and 5 after plasma treatment, cells were washed with PBS, trypsinized and counted using a Coulter counter. Cell proliferation was defined as fold change in attached cell number on day 5 compared to day 1.
E. 2D migration assay
Endothelial cell migration in response to plasma treatment was measured using a 2D migration assay. 48, 49 Approximately 30,000 cells were seeded inside 4-mm cloning rings on gridded cover slips placed in 6-well plates. A 5-mm glass bead was placed on top of the ring to provide tight contact with the coverslip, and samples were placed in an incubator. After 3 hours, the bead and ring were removed, and unattached cells were washed away with PBS. This process produced a confluent circle of attached cells. Cell samples were then treated with plasma (0-60 pulses). Untreated samples were the negative control, and FGF-2 (10 ng/ml) was the positive control. Images were captured at 0, 24, 48 and 72 hours after treatment in each direction (0, 90, 180 and 270°) using a Nikon Eclipse TS100 inverted phase contrast microscope equipped with a Nikon DS-Fi1 CCD camera. Migration distance, defined as the difference between cell migration fronts at 0 and 72 hours, was analyzed using ImageJ.
F. Three-dimensional migration assay
Three-dimensional migration was quantified using the QCM cell invasion assay kit (Millipore). In this assay, cells migrate through a collagen coated Transwell membrane with 8-µm pores and attach to the membrane bottom surface. Migrated cells are then fluorescently quantified by staining DNA following cell lysis. PAEC (1×10 5 cells) in 100 µl serum-free medium were added to the upper Boyden chamber compartment and plasma treated for 0-60 pulses. Then 150 µl DMEM with 10% FBS was added to the lower compartment. FGF-2 (10 ng/ml) was used as positive control and cells without plasma treatment as negative control. Samples were incubated at 37°C for 24 hours. Cells that migrated through the membrane were quantified according to the manufacturer's protocol. Briefly, residual cells from the upper compartment were removed using a cotton swab. After rinsing the inserts with PBS, cells on the membrane bottom surface were removed by incubating inserts in cell detachment solution for 30 min at 37°C. The detached cells were incubated in lysis buffer/CyQuant dye solution for 15 min at room temperature to stain the DNA. A volume of 150 µl cell lysis solution was then transferred to a 96-well plate and fluorescence was measured at ex/em: 480/520 nm using a microplate reader. Fluorescence was converted to cell number using a standard curve.
G. Tube formation assay
For the in vitro tube formation assay, 4 mg/ml rat tail type I collagen (BD Biosciences) was added to a 24-well plate and polymerized into a gel by incubating for 30 min at 37°C. PAEC (9 × 10 4 cells) were seeded on top of the gel and incubated for 24 hours at 37°C. Cells were plasma treated (0-60 pulses) in serum-free medium. Supplemented medium was then added, and medium was replaced every day. Phase contrast microscopy images were taken at 0, 24, 48 and 72 hours.
H. Statistical analysis
Statistical analyses were performed using Prism software (Graphpad). Data are expressed as mean ± SD. Comparisons between two groups were analyzed by Student's t-test, and trend over time was analyzed using one-way and two-way ANOVA.
III. RESULTS
A. Nitric oxide and nitrite increased in liquid and cells following PHD plasma treatment
Nitric oxide (NO) is a lipophilic small molecule which diffuses freely across plasma membrane into the cytoplasm. However, NO reacts with other ROS such as superoxide (O 2 -) and ozone (O 3 ) produced by plasma as well as O 2 in water to form the stable product NO 2 -. We therefore determined both NO and NO 2 -concentration in liquid following PHD plasma treatment. NO concentration increased linearly in PBS up to 240 pulses with both the straight and curved tubes, as measured by DAF-2. Between 1400 and 1600 nM NO was detected in PBS with the straight tube for 240 plasma pulses (240 sec) (Figure 2 ). In the curved tube configuration, approximately 900 nM NO was detected in PBS for the same treatment duration (p < 0.001). In PHD plasma treated PBS (curved tube configuration), NO 2 -concentration also increased in a dose-dependent manner (Figure 2 ). For a plasma treatment of 240 pulses, ~ 10 µM NO 2 -was detected in PBS. Intracellular NO concentration also increased with treatment time when cells were treated using the curved tube configuration. Approximately 150 nM NO was detected in endothelial cells immediately following 240 plasma pulses (Figure 2 ). Based on NO liquid concentration, approximately 11% of NO from plasma-treated PBS diffused through the cell membrane into the cytoplasm.
B. PHD plasma enhanced endothelial cell proliferation and migration
Increased cell proliferation was observed with PHD plasma treatment starting from day 3 after treatment. A rapid increase in attached cell number was observed for 5 pulses followed by a slow increase for up to 60 pulses. Samples treated with the highest plasma dose of 60 pulses had 2.7 times as many cells on day five as on day one, while control samples had only 2.5 times (Figure 3 , p < 0.01).
Endothelial cell 2D migration increased with PHD plasma 24 hours after treatment compared to untreated control. For 15 pulses, cells migrated 403 µm with plasma versus 290 µm without plasma (Figure 4a ). This difference was maintained up to 72 hours after plasma treatment [789 µm, 757 µm and 795 µm for 15, 30, and 60 pulses, respectively, compared to control (603 µm)].
Three-dimensional cell migration provides additional physiological relevance compared to 2D migration. PHD plasma treatment also increased 3D migration. Twenty-four hours after plasma treatment (0-60 pulses), the PAEC quantity that migrated through the chamber increased significantly (Figure 4b) . A plasma dose of 60 pulses increased the number of migrated cells by 16%.
C. PHD plasma did not induce tube formation
Endothelial cell tube formation following plasma treatment was tested for 0-60 plasma pulses. However, no tube formation was observed in any plasma treated samples up to 72 hours following treatment ( Figure 5 ). -increased linearly in plasma treated PBS and cells (NO only). NO was measured using DAF-2 in PBS and DAF-2 DA in cells. NO 2 -was measured using a Griess assay. p<0.0001 using ANOVA for all curves.
IV. DISCUSSION
NO is a key molecule involved in inflammation, vasodilation, and vascularization. Previously, we showed that a PHD plasma delivered NO into liquid and endothelial cells and induced a biological signaling response. 37 We now show that PHD plasma promoted endothelial cell proliferation and migration but not tube formation. These data suggest that PHD plasma treatment may be a useful tool for promoting vascularization, but additional modifications of the plasma device and/or plasma treatment regimen are needed.
Whereas measured NO concentration in liquid and cells increased linearly with plasma treatment, less NO was detected when the curved tube was used and even less NO was detected inside cells. Since NO is highly reactive, it is likely that NO delivered to the liquid decreased with the curved tube configuration due to interactions between plasma species and the tube walls. Although NO is a small lipophilic molecule that diffuses freely across the plasma membrane into the cytoplasm, it reacts with O 2 in water to form nitrite (NO 2 -) and nitrate (NO 3 -). We measured micromolar NO 2 -concentrations in liquid compared to nanomolar NO concentrations, showing that NO oxidation rapidly depletes the liquid NO level. Both nitrite and nitrate are also physiologically active species. Nitrite is commonly used as a vasodilator, can be reduced back to NO under physiological conditions, and may serve as a signaling molecule and gene expression regulator. 50 Dietary nitrate was also observed to decrease diastolic blood pressure in human subjects. 51 Thus even if the plasma source initially produces NO, it may be a combination of NO, NO 2 -, and NO 3 -that affect cell response. PHD plasma produces both reactive nitrogen and oxygen species; however we are confident that the results presented in this study relate to reactive nitrogen species for several reasons. A tube extension was attached to the plasma device for all experiments, which we previously showed essentially eliminated ROS that reached the cells. 37 In the same earlier study, we demonstrated that cGMP levels increased in PHD-plasma treated endothelial cells even in the presence of the ROS scavenger sodium pyruvate. cGMP is an important intracellular second messenger that mediates endothelial cell NO response and angiogenic pathways in particular.
The observed PHD plasma results are also significantly different from our observed results with a dielectric barrier discharge (DBD) plasma that primarily produces ROS. 41, 42 The optimal DBD plasma dose increased the fold change in cell number on day 5 by 66%, whereas the PHD plasma only increased cell number by 8%. Similarly, DBD plasma nearly doubled endothelial cell migration compared to more modest changes with PHD plasma. The decreased cell response to PHD plasma may be because the distinct signaling pathways activated by NO are not as potent as those activated by ROS. Alternatively, DBD plasma could have had a larger effect because the delivered ROS concentrations were significantly higher than the PHD plasma NO concentrations in the curved tube configuration.
While endothelial cell proliferation and migration were enhanced by PHD plasma, no tube formation was observed in plasma-treated samples. Higher NO concentrations FIGURE 4: PHD plasma treatment enhanced 2D and 3D endothelial cell migration. (a) PAEC 2D migration after plasma treatment was assessed using a cage assay. Migration distance was quantified by phase contrast microscopy 0, 24, 48, and 72 hours after treatment. (b) For 3D migration, PAEC were added to the top of a Boyden chamber and plasma treated. Migrated cells on the well bottom were measured. *p<0.01, **p<0.001, #p<0.05 compared to control.
Arjunan & Clyne and longer incubation times may be required for inducing tube formation in vitro. 52, 53 For example, to induce tube formation, Genis et al. incubated human umbilical vein endothelial cells (HUVEC) with NO donors DEA-NONOate and DETA-NONOate (100 µM) for 20 hours. 53 Another study by Schwalm et al. used the NO donor DETA-NO in high concentrations (500 µM) to induce tube formation. 52 Thus, multiple PHD plasma treatments over time may be required to provide sufficient NO for tube formation, or the PHD plasma could be used in a different configuration to simultaneously deliver both NO and ROS. In previous studies, ROS (specifically hydrogen peroxide, H 2 O 2 ) increased NO-induced cGMP activity. 54 We demonstrated that PHD plasma-produced NO enhanced endothelial cell proliferation and migration but not tube formation. However, these studies are not without limitations. We observed minor electrode degradation due to the high plasma discharge current and temperature. While these particulates did not affect endothelial cell morphology or viability in our experiments, electrode degradation should be avoided in future PHD plasma designs or its impact on cell and tissue function studied in greater detail. We also used serum-free medium in our studies, since serum is difficult to characterize and may have anti-oxidant properties. 55 Since serum would be present in a wound environment, specific serum and fluid thickness effects on plasma delivery of species should be determined.
In our earliest experiments, we observed similar cellular effects using NO donors such as DEA NONOate and the PHD plasma. We therefore believe that the primary benefit of PHD plasma for NO delivery is the ability to apply a defined NO dose with a small, portable device. Whereas both NO gas and donors produce similar physiological effects to PHD plasma-delivered NO, NO gas requires careful storage and the patient must travel to the doctor for treatment. NO donors similarly need careful storage as well as advanced delivery systems to ensure that the therapeutic dose is applied at the correct time for maximum effect. In contrast, the PHD plasma device could be operated by the patient at home or by a doctor in a remote location, and NO can be delivered at the prescribed time and dose without stability concerns. Furthermore, by modifying the PHD plasma device operating parameters, it may be possible to deliver both ROS and NO to maximize the angiogenic effect. Thus the PHD plasma device expands the therapeutic potential of NO in angiogenesis and wound healing.
V. CONCLUSIONS
We showed that a PHD plasma delivered NO into liquid and cells. PHD plasma with the curved tube extension increased endothelial cell proliferation and migration. However, the plasma dose and/or treatment time were not adequate to induce tube formation. The plasma electrical parameters, plasma treatment time, and/or treatment regimen can be varied to increase delivered NO and promote tube formation. This plasma may therefore be used as a novel method for administering NO to promote cell proliferation and migration.
